Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia

Mavuduru, Ravimohan; Pattanaik, Smita; Panda, Amlana; Agarwal, Mayank Mohan; Mathew, Joseph L; Singh, Shrawan Kumar; Mandal, Arup Kumar

doi:10.1002/14651858.cd010060

Cited by 9 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This 'industrial revolution' for BPO treatments has pioneered new solutions in both pharmacotherapy and surgery. Novel medical remedies have included the introduction of phosphodiesterase inhibitors (PDEIs) and phytotherapy [4, 5]. Meanwhile, surgery has fully embraced the minimally invasive approach, which has included the inauguration of laser treatments as well as non-ablative strategies such as Urolift [6].…”

Section: Introductionmentioning

confidence: 99%

The industrial revolution for the management of benign prostate obstruction: worldwide publication trends for surgical and medical therapies over the past two decades

Nettleton

Jones

Pietropaolo

et al. 2019

Cent european J Urol

View full text Add to dashboard Cite

Introduction Research for management of benign prostate obstruction (BPO) for adult males remains a cornerstone of urology research. This landscape has witnessed the rise and fall of multiple therapies, both surgical and medical. Our aim was to formally evaluate the publication trends for these interventions over the past 20 years. Material and methods A systematic search was performed in a Cochrane style. Data was analysed using the independent t-test and Pearson's correlation coefficient (SPSS version 24). To observe changes in trends more effectively, data was sub-divided into two time periods: 1997 to 2006 and 2007 to 2016. Results Over the past 20 years, 4236 papers have been published concerning for BPO (surgical, n = 2177 and medical, n = 2059). For surgical treatments, these included articles on monopolar transurethral resection of prostate (TURP) (n = 340), bipolar TURP (n = 260), HoLEP (n = 293) and Greenlight laser (n = 395). For medical therapies, these included alpha blockers (848), 5-alpha reductase inhibitors (n = 618) and PDE5I (n = 91). Between the two time periods the change was +18.8% (p = 0.108) for monopolar TURP, +497.1% (<0.001) for bipolar TURP, -54.5% (p <0.001 for prostatic stents and -81.9% (p <0.001) for transurethral microwave therapy (TUMT). There was over 290% rise in number of publications related to BPO laser surgery (p <0.001). For medical interventions, the change was +11.5% (p = 0.397) for alpha blockers, -1.9% (p = 0.867), +49.0%( 0.122) for phytotherapy, +2075% (p <0.001) for PDEI and +2375.0% (p <0.001) for combined alpha blocker and anti-muscarinics. Conclusions Interventions for BPO have undergone a high volume of research. In particular, minimally invasive laser surgeries and combined medical therapies have seen significant expansion.

show abstract

Section: Introductionmentioning

confidence: 99%